<DOC>
	<DOCNO>NCT02275910</DOCNO>
	<brief_summary>This Phase 1 study E7090 subject advance solid tumor . This study conduct 2 part : 1 . Part 1 dose escalation portion study determine maximum tolerate dose subject solid tumor , 2 . Part 2 comprise cohort expansion characterize safety tolerability E7090 ass preliminary efficacy E7090 subject solid tumor characterize genetic abnormality FGF/FGFR pathway .</brief_summary>
	<brief_title>Phase 1 Study E7090 Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<criteria>Part 1and Part 2 1 . Provide write informed consent 2 . Male female subject age &gt; = 20 year time inform consent 3 . Subjects histological and/or cytological diagnosis solid tumor 4 . Subjects fail standard therapy , appropriate treatment available . 5 . Subjects Performance Status ( PS ) score 01 established Eastern Cooperative Oncology Group ( ECOG ) 6 . Subjects expect survive 3 month longer start administration investigational drug . Part 2 7 . Subjects tumor express genetic abnormality FGF/FGFR ( fibroblast growth factor/ fibroblast growth factor receptor ) pathway . Exclusion criteria 1 . Patients brain metastasis clinical symptom require treatment . 2 . Medical history clinically significant cardiovascular impairment 3 . Concomitant systemic infection require medical treatment 4 . Effusion require drainage 5 . Known intolerance study drug ( excipients ) 6 . Subjects whose toxicity previous treatment recover Grade 1 low ( except alopecia ) . 7 . Inability take oral medication , malabsorption syndrome , uncontrolled gastrointestinal condition ( e.g. , nausea , diarrhea , vomit ) might impair bioavailability E7090 . 8 . Psychiatric disorder ( e.g. , alcohol drug dependency ) judge ineligible study entry investigator subinvestigator 9 . Females pregnant breastfeed 10 . Any subject judge principal investigator investigator inappropriate subject clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>E7090</keyword>
</DOC>